Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Biohaven Pharmaceutical Holding Co stock (BHVN)

Buy Biohaven Pharmaceutical Holding Co stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Biohaven Pharmaceutical Holding Co is a biotechnology business based in the US. Biohaven Pharmaceutical Holding Co shares (BHVN) are listed on the NYSE and all prices are listed in US Dollars. Biohaven Pharmaceutical Holding Co employs 239 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Biohaven Pharmaceutical Holding Co stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Biohaven Pharmaceutical Holding Co stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BHVN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Biohaven Pharmaceutical Holding Co stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Not rated yet
OPTO
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biohaven Pharmaceutical Holding Co stock price (NYSE: BHVN)

Use our graph to track the performance of BHVN stocks over time.

Biohaven Pharmaceutical Holding Co shares at a glance

Information last updated 2024-07-15.
Latest market close$38.09
52-week range$16.45 - $62.21
50-day moving average $36.06
200-day moving average $39.42
Wall St. target price$58.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-6.90

Is it a good time to buy Biohaven Pharmaceutical Holding Co stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biohaven Pharmaceutical Holding Co price performance over time

Historical closes compared with the close of $38.09 from 2024-07-12

1 week (2024-07-09) 7.96%
1 month (2024-06-14) 12.59%
3 months (2024-04-16) -12.98%
6 months (2024-01-16) -14.60%
1 year (2023-07-14) 58.25%
2 years (2022-07-15) -73.91%
3 years (2021-07-16) 125.83
5 years (2019-07-16) 45.3

Biohaven Pharmaceutical Holding Co financials

Gross profit TTM $0
Return on assets TTM -65.27%
Return on equity TTM -133.69%
Profit margin 0%
Book value $3.69
Market Capitalization $3.4 billion

TTM: trailing 12 months

Biohaven Pharmaceutical Holding Co share dividends

We're not expecting Biohaven Pharmaceutical Holding Co to pay a dividend over the next 12 months.

Biohaven Pharmaceutical Holding Co overview

Biohaven Ltd. , together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc. , Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co.

Frequently asked questions

What percentage of Biohaven Pharmaceutical Holding Co is owned by insiders or institutions?
Currently 12.849% of Biohaven Pharmaceutical Holding Co shares are held by insiders and 86.037% by institutions.
How many people work for Biohaven Pharmaceutical Holding Co?
Latest data suggests 239 work at Biohaven Pharmaceutical Holding Co.
When does the fiscal year end for Biohaven Pharmaceutical Holding Co?
Biohaven Pharmaceutical Holding Co's fiscal year ends in December.
Where is Biohaven Pharmaceutical Holding Co based?
Biohaven Pharmaceutical Holding Co's address is: 215 Church Street, New Haven, CT, United States, 06510
What is Biohaven Pharmaceutical Holding Co's ISIN number?
Biohaven Pharmaceutical Holding Co's international securities identification number is: VGG111961055

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site